TheraRadar
← Back
Data updated: Mar 29, 2026

PTC THERAP

OncologyRespiratoryNeurology
Pharma

PTC THERAP is a pharmaceutical company focused on Oncology, Respiratory, Neurology. Key products include SEPHIENCE.

2017
Since
2
Drugs
-
Trials
3
Approved (2yr)

Key Drugs

SEPHIENCE
sepiapterin
PAH 2 indications · 2025
EMFLAZA
deflazacort
Rare Disease
Glucocorticoid receptor 1 indications · 2017

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

SEPHIENCE 2025-07-28
Type 1 - New Molecular Entity
EMFLAZA 2024-06-05
Labeling
EMFLAZA 2024-06-05
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 45%
0 drugs Phase 2: 1 Phase 1: 3
Respiratory 36%
0 drugs Phase 3: 1
Neurology 18%
0 drugs Phase 2: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

GSK big-pharma
Respiratory, Oncology, Neurology
Roche big-pharma
Oncology, Neurology, Respiratory
GE HEALTHCARE specialty
Neurology, Oncology, Respiratory
Novartis big-pharma
Oncology, Respiratory
ENDO OPERATIONS specialty
Oncology, Respiratory, Neurology